Report Description Table of Contents Ustekinumab Market: How Are Biosimilar Launches Reshaping Revenue Across Inflammatory Disease Treatments? According to Strategic Market Research, the Global Ustekinumab Market was valued at USD 7.29 billion in 2025 and is projected to reach USD 8.49 billion by 2032, expanding at a CAGR of 2.2% during 2026–2032. Demand is supported by ustekinumab treatment across Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. However, the market is entering a significant competitive transition as multiple biosimilars expand treatment availability and challenge the established position of Stelara. A substantial inflammatory bowel disease population supports the underlying treatment opportunity. According to the U.S. Centers for Disease Control and Prevention, approximately 4.11 million U.S. adults had been diagnosed with inflammatory bowel disease during 2023–2024, including 1.26 million with Crohn's disease and 3.15 million with ulcerative colitis. This represents a broad disease population rather than the number eligible for ustekinumab, as treatment is concentrated among patients meeting clinical criteria for advanced therapy. Stelara revenue demonstrates the commercial impact of biosimilar competition. Johnson & Johnson reported approximately USD 6.1 billion in worldwide Stelara sales in 2025, including approximately USD 3.8 billion in U.S. sales. During the first nine months of 2026, worldwide Stelara revenue declined 56.4% to USD 2.11 billion, compared with USD 4.85 billion during the corresponding period of 2025. The decline reflects increasing biosimilar competition and changing treatment preferences. These figures demonstrate the pressure on originator revenue while the broader ustekinumab market continues to serve established patient populations. Eight FDA-approved biosimilars have expanded competition against Stelara in the United States. The FDA's biosimilar product database lists Wezlana, Selarsdi, Pyzchiva, Otulfi, Imuldosa, Yesintek, Steqeyma, and Starjemza. Their development and commercialization involve companies including Amgen, Alvotech, Teva, Samsung Bioepis, Sandoz, Fresenius Kabi, Accord BioPharma, Biocon Biologics, Celltrion, and Bio-Thera. The expanding product base is increasing competition across psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis treatments. Commercial launches are translating biosimilar approvals into measurable market penetration. Celltrion's Steqeyma reached a reported 16.2% share of the U.S. ustekinumab market by July 2026, compared with 10.2% in February 2026, according to IQVIA data cited in September 2026. This demonstrates the speed at which newer biosimilars are gaining commercial presence. Biocon Biologics launched Yesintek in February 2025, while Teva and Alvotech introduced Selarsdi in the U.S. in February 2025. These launches have expanded the range of commercially available ustekinumab alternatives. Originator and biosimilar manufacturers are competing across multiple inflammatory disease indications. Amgen's Wezlana was the first FDA-approved interchangeable biosimilar to Stelara. Amgen reported USD 273 million in Wezlana/Wezenla sales during 2025, reflecting early commercial traction. Meanwhile, Samsung Bioepis and Sandoz's Pyzchiva and Fresenius Kabi's Otulfi further expand the competitive product portfolio. Regulatory expansion is extending the potential treatment population. Stelara's original approvals across plaque psoriasis and psoriatic arthritis were followed by FDA approvals for Crohn's disease in 2016 and ulcerative colitis in 2019. In 2026, the FDA expanded its pediatric indications, including Crohn's disease and ulcerative colitis. These developments reinforce the importance of maintaining indication coverage across adult and pediatric inflammatory disease populations. FDA drug information. The Global Ustekinumab Market is projected to generate approximately USD 1.20 billion in additional annual revenue by 2032, although increasing biosimilar penetration is reshaping the distribution of revenue between originator and competing manufacturers. The eight FDA-approved biosimilars, combined with established products from Johnson & Johnson, Amgen, Alvotech, Teva, Biocon Biologics, Celltrion, Samsung Bioepis, and Fresenius Kabi, are intensifying competition. Future market performance will depend on biosimilar uptake, treatment access, indication coverage, and the ability of manufacturers to maintain patient volumes as Stelara faces continued revenue erosion. Which Ustekinumab Market Segments Lead the Industry and Offer the Strongest Expansion Opportunities? By Product Type: Biosimilar Launches Shift Revenue Away From the Originator Leading Subsegment: Reference Ustekinumab (Originator) Reference ustekinumab, marketed as Stelara, dominated the global Ustekinumab Market with an estimated 80% share, valued at USD 5.832 billion in 2025. As the original biologic therapy, Stelara remains the established clinical benchmark for ustekinumab biosimilars and unbranded equivalents, supported by its extensive clinical evidence, established prescribing practices, and longstanding use in immune-mediated inflammatory diseases. However, increasing biosimilar competition and the gradual transition toward lower-cost alternatives are expected to contribute to a CAGR of −3.20% during 2026–2032. Fastest-Growing Subsegment: Ustekinumab Biosimilars Ustekinumab biosimilars represented an estimated 20% share of the global Ustekinumab Market, valued at USD 1.458 billion in 2025, and are projected to record the fastest CAGR of 14.86% during 2026–2032. As lower-cost alternatives to the reference biologic Stelara (ustekinumab), biosimilars are expanding treatment accessibility across psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Increasing biosimilar approvals, favorable reimbursement policies, and growing physician acceptance are accelerating treatment adoption, while competitive pricing supports broader patient access and healthcare expenditure optimization. By Indication: Long-Term Bowel Disease Treatment Sustains Biologic Demand Leading and Fastest-Growing Subsegment: Inflammatory Bowel Diseases (Crohn’s Disease and Ulcerative Colitis) Inflammatory bowel diseases (IBD) represent the largest and fastest-growing indication in the Ustekinumab Market, accounting for approximately 55% market share, valued at USD 4.010 billion in 2025, with a projected CAGR of 2.92% during 2026–2032. Ustekinumab, marketed as Stelara, is an approved monoclonal antibody treatment for moderately to severely active Crohn’s disease and ulcerative colitis. Its established clinical efficacy, sustained use in maintenance therapy, and increasing adoption of targeted biologic treatments support its significant commercial position across inflammatory bowel disease management. By Route of Administration: Infusion Initiates Treatment and Injections Sustain Maintenance Leading Subsegment: Subcutaneous Injection Subcutaneous injection dominates the Ustekinumab Market, accounting for an estimated 85% market share, equivalent to USD 6.197 billion in 2025, with a projected CAGR of 1.90% during 2026–2032. Subcutaneous administration plays a central role in long-term maintenance therapy for psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Its established use in maintenance regimens, convenient administration, and suitability for at-home treatment support continued clinical adoption. The availability of subcutaneous ustekinumab biosimilars further strengthens treatment accessibility and commercial opportunities across major healthcare markets. Fastest-Growing Subsegment: Intravenous Infusion Intravenous infusion accounted for an estimated 15% share of the global Ustekinumab Market, valued at USD 1.094 billion in 2025, and is projected to register the fastest CAGR of 3.81% during 2026–2032. Intravenous ustekinumab, marketed as Stelara, is administered as a single weight-based induction dose for patients with moderately to severely active Crohn’s disease and ulcerative colitis. Its established role in initiating treatment for inflammatory bowel diseases supports continued clinical utilization, particularly among patients requiring advanced biologic therapy. By End User: Hospital Initiation and Home Dosing Shape Treatment Access Leading Subsegment: Hospitals Hospitals represented the largest end-user category in the Ustekinumab Market, accounting for an estimated 50% market share and USD 3.645 billion in 2025, with a projected CAGR of 1.20% during 2026–2032. Hospitals and specialized medical centers play a central role in ustekinumab administration, treatment initiation, safety monitoring, and long-term management of patients with psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Established biologic treatment infrastructure, specialist supervision, and access to infusion facilities support the continued importance of hospital-based ustekinumab therapy. Fastest-Growing Subsegment: Homecare Settings Homecare settings play a critical role in the maintenance phase of Ustekinumab (Stelara) therapy, particularly for patients with psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis requiring long-term treatment. Homecare settings accounted for an estimated 20% market share, representing USD 1.458 billion in 2025, and are projected to register the fastest CAGR of 4.07% during 2026–2032. Increasing adoption of subcutaneous self-administration, convenient maintenance dosing schedules, and reduced hospital visits supports the growing preference for home-based ustekinumab treatment. By Geography: U.S. Biosimilar Launches and Wider Access in Asia-Pacific Shift Market Growth Leading Region: North America North America dominated the global ustekinumab market, accounting for approximately 61% of the global market, valued at USD 4.447 billion in 2025, with a projected CAGR of 1.20% during 2026–2032. The region is witnessing accelerated adoption of ustekinumab biosimilars following key patent expirations and multiple commercial launches. Increasing biosimilar availability, expanding insurance coverage, and competitive pricing are reshaping treatment accessibility across psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, while encouraging healthcare providers and payers to transition toward cost-effective ustekinumab alternatives. Fastest-Growing Region: Asia-Pacific Asia-Pacific accounted for an estimated 10% share of the global Ustekinumab Market, valued at USD 0.729 billion in 2025, and is projected to record the fastest regional CAGR of 5.51% during 2026–2032. Expanding adoption of ustekinumab and its biosimilars across China, Japan, India, and South Korea is supported by evolving regulatory approvals, increasing treatment accessibility, and broader clinical use in psoriasis, psoriatic arthritis, and inflammatory bowel disease. Biosimilar launches and improving reimbursement coverage are expected to strengthen treatment penetration across the region. Which Companies Are Shaping the Competitive Landscape of the Ustekinumab Market? Johnson & Johnson (Janssen Biotech): Stelara’s Prescribing Base Faces Biosimilar Pricing Pressure Johnson & Johnson, through Janssen Biotech, is the leading originator manufacturer in the global ustekinumab market, with its established biologic medicine, Stelara, approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. The reference ustekinumab segment accounted for an estimated 80% of the global market, equivalent to USD 5.832 billion in 2025, highlighting the significant commercial position of originator therapy. This figure represents the estimated originator segment rather than Johnson & Johnson's independently reported sales. Stelara's established prescribing history, broad therapeutic indications, and specialist physician familiarity support its competitive position. However, increasing biosimilar availability is reshaping the company's market position through pricing competition, payer negotiations, and shifting treatment preferences. Other Key Companies and Their Market Roles: Amgen: Competes through Wezlana, its ustekinumab biosimilar, expanding treatment alternatives across inflammatory disease indications and strengthening competition with Stelara. Samsung Bioepis: Participates through Pyzchiva, its ustekinumab biosimilar developed for multiple immune-mediated inflammatory conditions, supporting biosimilar competition in international markets. Celltrion: Commercializes Steqeyma, an ustekinumab biosimilar, strengthening its immunology portfolio and expanding competition across psoriasis, psoriatic arthritis, and inflammatory bowel disease treatment. Biocon Biologics: Participates through Yesintek, its ustekinumab biosimilar, targeting opportunities associated with affordable biologic treatment and wider access to established immunology therapies. Analyst Commentary: How Will Formulary Access and Supply Reliability Shape Biosimilar Competition? The Ustekinumab Market is entering a biosimilar-driven competitive phase, where pricing strategies, payer formulary access, and physician prescribing preferences will determine market share. Biosimilar manufacturers have opportunities to capture originator revenue through competitive contracting and expanded treatment access, particularly in inflammatory bowel diseases. Long-term commercial success will depend on reimbursement positioning, reliable supply, and effective specialty pharmacy distribution. Ustekinumab Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 7.29 Billion Revenue Forecast in 2032 USD 8.49 Billion Overall Growth Rate CAGR of 2.2% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Product Type, By Indication, By Route of Administration, By End User, By Geography By Product Type Reference Ustekinumab, Ustekinumab Biosimilars, Other Ustekinumab Products By Indication Inflammatory Bowel Diseases, Plaque Psoriasis, Psoriatic Arthritis By Route of Administration Subcutaneous Injection, Intravenous Infusion, Other Administration Routes By End User Hospitals, Specialty Clinics, Homecare Settings By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Demand for advanced treatment of Crohn’s disease and ulcerative colitis, established ustekinumab use in plaque psoriasis and psoriatic arthritis, and biosimilar launches that broaden treatment availability Customization Option Available upon request Frequently Asked Question About This Report Q1. What factors are shaping the Ustekinumab Market? A1. Demand is supported by ustekinumab use across Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Biosimilar launches and broader treatment access are also reshaping market dynamics. Q2. How are biosimilars changing the competitive landscape? A2. Biosimilars are rapidly expanding treatment alternatives and increasing pricing competition. The biosimilar segment is projected to grow at a CAGR of 14.86% during 2026–2032, while originator ustekinumab is projected to decline. Q3. Which indication represents the largest opportunity in the market? A3. Inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis, account for an estimated 55% of the market in 2025. Continued maintenance therapy and established biologic use support this leading position. Q4. Why is homecare becoming more important in the industry? A4. Homecare settings are projected to record the fastest end-user CAGR of 4.07% during 2026–2032. The growing use of subcutaneous maintenance injections supports self-administration and reduces the need for frequent hospital visits. Q5. Which route of administration is growing fastest in the market? A5. Intravenous infusion is projected to record the fastest route CAGR of 3.81% during 2026–2032. Its role as an induction treatment for Crohn’s disease and ulcerative colitis supports continued utilization. Q6. Which region is expected to expand the fastest? A6. Asia-Pacific is projected to record the fastest regional CAGR of 5.51% during 2026–2032. Growth is supported by expanding biologic access, biosimilar adoption, regulatory developments, and improving reimbursement across major markets. Sources: Johnson & Johnson – Stelara generated USD 6.078 billion in worldwide sales in 2025, including USD 3.847 billion in the United States. Johnson & Johnson – Full-year 2025 results and Stelara sales by geography Johnson & Johnson – Worldwide Stelara sales fell 56.4% to USD 2.112 billion in the first nine months of 2026. Johnson & Johnson – Q3 2026 product sales · SEC – Q3 2026 Form 10-Q U.S. FDA – Eight approved biosimilars reference Stelara. FDA – Approved biosimilar products and reference biologics Celltrion – Steqeyma’s reported U.S. ustekinumab market share reached 16.2% in July 2026, up from 10.2% in February. Celltrion – September 2026 Steqeyma market share and formulary update Amgen – Wezlana and Wezenla generated USD 273 million in combined worldwide sales in 2025. Amgen – Full-year 2025 biosimilar sales · FDA – Wezlana interchangeable biosimilar approval U.S. FDA – Stelara gained two pediatric IBD indications in 2026 for patients aged two years and older. FDA – Pediatric Crohn’s disease approval · FDA – Pediatric ulcerative colitis approval CDC and NCHS – An estimated 4.108 million U.S. adults had ever received an IBD diagnosis, based on the 2023–2024 survey. CDC – Diagnosed inflammatory bowel disease among U.S. adults, 2023–2024 U.S. National Library of Medicine – Adult Stelara treatment for Crohn’s disease and ulcerative colitis starts with one IV infusion, followed by subcutaneous maintenance every eight weeks. DailyMed – Stelara prescribing information and administration routes U.S. CMS – Stelara’s 2026 Medicare negotiated price was USD 4,695 per 30-day supply, 66% below its 2023 list price. CMS – 2026 negotiated price for Stelara · CMS – Selected Drug List and removal dates Teva and Alvotech – Selarsdi became commercially available in the United States on February 21, 2025. Alvotech – U.S. commercial launch of Selarsdi Biocon Biologics – Yesintek launched in the United States on February 24, 2025, in four presentations. Biocon – Yesintek U.S. launch and available formulations Sandoz – Pyzchiva launched in the United States in February 2025. Sandoz – Full-year 2025 results and Pyzchiva U.S. launch Fresenius Kabi and Formycon – Otulfi became available in the United States on March 3, 2025. Fresenius Kabi – Otulfi U.S. commercial availability Table of Contents - Global Ustekinumab Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Indication, Route of Administration, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Indication, Route of Administration, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Indication, Route of Administration, and End User Originator Ustekinumab and Biosimilar Market Positioning Investment Opportunities in the Ustekinumab Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Ustekinumab Biosimilars, Inflammatory Bowel Disease Treatments, Psoriasis Therapies, and Psoriatic Arthritis Management Opportunities in Biosimilar Commercialization, Payer Adoption, Specialty Pharmacy Distribution, and Treatment Access Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Therapeutic Role of Ustekinumab in Crohn’s Disease, Ulcerative Colitis, Plaque Psoriasis, and Psoriatic Arthritis Originator Stelara and the Expansion of Ustekinumab Biosimilars Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Historical Market Assessment (2019–2024) Base Year Market Assessment (2025) Forecast Modeling and Assumptions (2026–2032) Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory Approvals and Biosimilar Competition Role of Biosimilar Commercialization, Payer Adoption, and Competitive Pricing in Market Expansion Impact of Indication Coverage, Treatment Access, and Physician Prescribing Preferences Originator Revenue Erosion and Changing Market Competition During 2025–2026 Global Ustekinumab Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: Reference Ustekinumab (Originator) Ustekinumab Biosimilars Other Ustekinumab Products Market Analysis by Indication: Inflammatory Bowel Diseases Crohn’s Disease Ulcerative Colitis Plaque Psoriasis Psoriatic Arthritis Market Analysis by Route of Administration: Subcutaneous Injection Intravenous Infusion Other Administration Routes Market Analysis by End User: Hospitals Specialty Clinics Homecare Settings Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Ustekinumab Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Indication, Route of Administration, and End User Country-Level Breakdown: United States Canada Mexico Europe Ustekinumab Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Indication, Route of Administration, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific Ustekinumab Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Indication, Route of Administration, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Ustekinumab Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Indication, Route of Administration, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Ustekinumab Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Indication, Route of Administration, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Johnson & Johnson Amgen Inc. Alvotech Teva Pharmaceutical Industries Ltd. Samsung Bioepis Sandoz Group AG Fresenius Kabi Accord BioPharma Biocon Biologics Celltrion, Inc. Bio-Thera Solutions Pfizer Inc. UCB S.A. Novartis AG Competitive Landscape and Strategic Insights Benchmarking Based on Biosimilar Portfolios, Indication Coverage, Regulatory Approvals, Product Availability, and Regional Presence Originator Stelara Market Positioning Ustekinumab Biosimilar Commercialization and Market Penetration FDA-Approved Biosimilar Product Portfolio Analysis Wezlana, Selarsdi, Pyzchiva, Otulfi, Imuldosa, Yesintek, Steqeyma, and Starjemza Competitive Positioning Biosimilar Pricing, Payer Adoption, and Formulary Access Strategies Research, Development, and Regulatory Expansion Across Inflammatory Disease Indications Appendix Abbreviations and Terminologies Used in the Report References and Sources Regulatory and Product Approval References Market Definitions and Segmentation Scope List of Tables Market Size by Product Type, Indication, Route of Administration, End User, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Market Size Analysis (2025), and Market Forecasts (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Country-Level Market Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Originator and Biosimilar Competitive Benchmarking FDA-Approved Ustekinumab Biosimilar Product Overview Competitive Benchmarking of Leading Vendors Indication Coverage and Regulatory Approval Analysis List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Indication, Route of Administration, and End User (2025 vs. 2032) Originator Stelara Revenue Trends and Biosimilar Competition During 2025–2026 Ustekinumab Biosimilar Launch and Market Penetration Trends Global Ustekinumab Ecosystem and Value Chain Analysis